Last Updated on 30th July 2020

MGC Pharmaceuticals has gained formal approval from the Health Products Regulatory Authority (HRPA) for the sale of its CannEpil products in Ireland.

CannEpil uses a high CBD, low THC formula that has been used to treat epilepsy. It is now set to be one of the very first cannabinoid-based medicines approved under the Irish Government’s Medical Cannabis Access Programme for prescription and sale.

“Access to the Irish market is a key achievement for the company,” Roby Zomer, the MGC Pharma Managing Director and Co-Founder said.

“Not only does it allow MGC Pharma's GMP certified medical products to reach more patients in need, but can be seen as a catalyst for fast-tracking follow-on approval applications to prescribe in other EU member state countries such as Germany, Austria, Italy and France.”

The products will be imported by Grow Biotech a British-based company which is an industry leader in bridging the gap between existing cannabis medicines and accepted pharmaceutical standards.

With approval for CannEpil gained, MGC Pharma is hoping to use that to their advantage in other countries in the EU.